Last reviewed · How we verify
Consolidation Carboplatin
Carboplatin works by interfering with DNA replication in cancer cells, leading to cell death.
Carboplatin works by interfering with DNA replication in cancer cells, leading to cell death. Used for Ovarian cancer, Non-small cell lung cancer, Breast cancer.
At a glance
| Generic name | Consolidation Carboplatin |
|---|---|
| Sponsor | Radiation Therapy Oncology Group |
| Drug class | Platinum-based chemotherapy |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Carboplatin is a platinum-based chemotherapy drug that binds to DNA, causing cross-links and inhibiting DNA replication. This leads to cell death, particularly in rapidly dividing cancer cells. The exact mechanism is not fully understood, but it is thought to involve the formation of platinum-DNA adducts that trigger apoptosis.
Approved indications
- Ovarian cancer
- Non-small cell lung cancer
- Breast cancer
- Testicular cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (PHASE1)
- Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Consolidation Carboplatin CI brief — competitive landscape report
- Consolidation Carboplatin updates RSS · CI watch RSS
- Radiation Therapy Oncology Group portfolio CI